fda 503b bulks list bpc-157 Peptides in 2026, What the Review Means FDA's Overreach on Compounded Peptides
FDA's Overreach on Compounded Peptides BPC 157: Dosage, Benefits, FDA Status & Clinics (2026) The FDA just dropped a 68 page PDF on if BPC 157 should be legal or not to compound. Their initial recommendation: DO NOT add BPC 157 to the 503A Bulks List. They're meeting this FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them FDA Removes Peptides from Category 2 List, Paving Way for Regulation Jonathan Cole posted on the topic LinkedIn
Pay in 4 interest-free payments of $7.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 17 - Sep 22


